评估表皮生长因子受体靶向放射性免疫金纳米颗粒作为肿瘤动物模型中的治疗诊断试剂。

Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.

机构信息

Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei 112, Taiwan, ROC.

出版信息

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3180-5. doi: 10.1016/j.bmcl.2013.04.002. Epub 2013 Apr 10.

DOI:10.1016/j.bmcl.2013.04.002

PMID:23628334

Abstract

This study evaluated the tumor targeting and therapeutic efficacy of a novel theranostic agent (131)I-labeled immuno-gold-nanoparticle ((131)I-C225-AuNPs-PEG) for high epidermal growth factor receptor (EGFR)-expressed A549 human lung cancer. Confocal microscopy demonstrated the specific uptake of C225-AuNPs-PEG in A549 cells. (131)I-C225-AuNPs-PEG induced a significant reduction in cell viability, which was not observed when incubated with AuNPs-PEG and C225-AuNPs-PEG. MicroSPECT/CT imaging of tumor-bearing mice after intravenous injection of (123)I-C225-AuNPs-PEG revealed significant radioactivity retention in tumor suggested that (131)I-labeled C225-conjugated radioimmuno-gold-nanoparticles may provide a new approach of targeted imaging and therapy towards high EGFR-expressed cancers.

摘要

本研究评估了一种新型治疗诊断试剂（131）I 标记免疫金纳米颗粒（（131）I-C225-AuNPs-PEG）对高表皮生长因子受体（EGFR）表达的 A549 人肺癌的肿瘤靶向和治疗效果。共聚焦显微镜显示 C225-AuNPs-PEG 特异性摄取 A549 细胞。（131）I-C225-AuNPs-PEG 导致细胞活力显著降低，而与 AuNPs-PEG 和 C225-AuNPs-PEG 孵育时则未观察到这种情况。荷瘤小鼠静脉注射（123）I-C225-AuNPs-PEG 后进行 MicroSPECT/CT 成像，显示肿瘤中存在显著的放射性滞留，表明（131）I 标记的 C225 结合放射性免疫金纳米颗粒可能为高 EGFR 表达癌症的靶向成像和治疗提供新方法。